1. Skip to header
  2. Skip to main
  3. Skip to content
  4. Skip to sidebar
  5. Skip to footer
  • Home > Blog > Clinical Trial > Clinical Trial Spotlight: Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma
Posted on Wednesday, Dec 9, 2009

Clinical Trial Spotlight: Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma

Study: Phase II Study of Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity

Start Date: December 2009
End Date: December 2011

Recruiting Contacts:
Contact: Lee Krug, MD (212)639-8420
Contact: Christopher Azzoli, MD (212)639-2131

Information:
Memorial Sloan-Kettering Cancer Center is conducting a clinical trial for patients with a confirmed diagnosis of epithelioid, sarcomatoid, or mixed-type malignant pleural mesothelioma that is not amenable to surgery for treatment with everolimus.

The purpose of this study is to find out what effects, both good and bad, that everolimus has on the cancer. Everolimus works by blocking a protein that helps the cancer grow. The goal of this clinical research study is to learn if the study drug everolimus can shrink or slow the growth of mesothelioma.

The enrollment goal for this study is 39 participants. At the end of the study, if 17 or more patients show clinical benefit out of a total of 39 patients enrolled, the regimen will be considered worthy of further investigation.

For complete information see ClinicalTrials.